DX&VX Selected for Korea's First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology
* Pioneering Korea's ARPA-H Project: Focused on mRNA Vaccine Room-Temperature Storage and Extra-Long-Term Preservation * Creating a Platform for Prolonged Room-Temperature Storage and Efficient Distribution of mRNA Vaccines SEOUL, South Korea, Nov. 1, 2024 /PRNewswire/ -- OnOctober 30, a Ko...
World-Renowned Scientist Wah Chiu, Stanford University Professor and Honorary Advisor to Pohang City, visited Korea at the invitation of the Coree Group
- Seminar presentation at the invitation of Dx&Vx and Coree Group SEOUL, South Korea, Aug. 26, 2024 /PRNewswire/ -- Professor Wah Chiu, who visited Korea at the invitation of the Coree Group, led by ChairmanLim Chong Yoon, an inside director of Hanmi Pharmaceutical and the largest shareholder of ...
DX&VX is on Track and Accelerating the Development of Oral Obesity Treatment
* Confirmation of effects compared to global late-stage clinical trials * Accelerating the development of obesity treatment through early licensing out, global joint clinical trials, research funding investment, etc. SEOUL, South Korea, July 18, 2024 /PRNewswire/ -- DX&VX, which is gaining att...
Inaugural 'Korea Medical Innovation Research Forum' regular seminar, a success
* To be registered as an official research organization by the National Assembly Secretariat... Expected to become Korea's leading medical think tank * Planning to initiate global multinational clinical projects in digital therapeutics * Establishing a future medical system centered aroun...
Mr. Chong-Yoon Lim, Chairman of COREE Group emphasizes "Creative destruction and Healthcare 4.0" [New Year Message at X-Twitter SNS]
SEOUL, South Korea, Jan. 3, 2024 /PRNewswire/ -- Chong-Yoon Lim, Chairman of COREE group, President of Hanmi pharmaceutical company and Former Chairman of Korea Biotechnology Industry Organization (The largest shareholder group of Coree HK, Hanmi (KOSPI) and Dx&Vx (KOSDAQ), as well), highlighted ...
Dx&Vx co-develops a bio-healthcare big data platform with LG CNS
- Possessing human genome and microbiome data in all clinical stages - Becoming a global bio-healthcare big data platform company SEOUL, South Korea, Dec. 20, 2023 /PRNewswire/ -- Dx&Vx will develop a bio-healthcare big data platform utilizing AI technology provided by LG CNS. Dx&Vx recently anno...
DxVx, plans to make a license-in agreement of OVM-200 and conduct clinical trials in Asia
- Final stage in licensing OVM-200 from Oxford Vacmedix in the UK - DxVx plans to proceed its own clinical trials in Asia, including Korea and China SEOUL, South Korea, Nov. 24, 2023 /PRNewswire/ -- DxVx announces today that it will conduct its own clinical trials of OVM-200, an anti-cancer vacc...
DxVx, won the governmental project to develop diagnostic sensor kit for adult diseases
* National Project converging semiconductor and biotechnology SEOUL, South Korea, June 9, 2023 /PRNewswire/ -- DxVx announced today that it won the national project, 'Korea-led K-Sensor Technology Development for Market Leadership' supported by the Ministry of Trade, Industry and Energy and man...
Avixgen accelerates the progress on new drug pipeline development
- Pipeline development updates on age related macular degeneration, dry eye disease and atopic dermatitis SEOUL, South Korea, May 24, 2023 /PRNewswire/ -- DxVx has released development updates on the pipelines of its recently acquired company, Avixgen. DxVx acquired about 63% stake of Avixgen, w...
DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president
- Reorganizing the global sales networks and enhancing its capabilities to get global approvals for new drug - Accelerating value of the new drug pipelines SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointedYong Gu Lee as the new CEO and ...
DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200
SEOUL, South Korea, March 30, 2023 /PRNewswire/ -- DXVX announces that its affiliated company Oxford Vacmedix (OVM) has completed Phase 1a trial of cancer vaccine and plans to proceed Phase1b trial of OVM-200. DxVx Co., Ltd. is the Korean Stock market (KOSDAQ) listed company and is the largest s...
Research Collaboration between Prof. Antonio Gasbarrini team at Gemelli Hospital and Asian Biotech companies, Coree and Dx&Vx
SEOUL, South Korea, Oct. 13, 2022 /PRNewswire/ -- According to International Diabetes Federation, approximately 537 million adults (20-79 years) are living with diabetes worldwide and 206 million adults of the Western Pacific region includingChina, Japan, and South Korea have diabetes in 2021. St...
